Metabolism, Inborn Errors Clinical Trial
OBJECTIVES: I. Determine the phenotypic heterogeneity of patients with genetic disorders
including their clinical spectrum and natural history.
II. Develop and evaluate novel methods for the treatment of genetic disorders including
metabolic manipulation, enzyme manipulation, enzyme replacement, enzyme transplantation, and
gene transfer techniques in these patients.
III. Develop and evaluate methods for the prenatal diagnosis of genetic disorders using
improved cytogenetic, biochemical, and nucleic acid techniques and amniotic fluid cells or
chorionic villi in these patients.
PROTOCOL OUTLINE:
Patients are evaluated annually or biannually, depending on disease status and progression.
Patients undergo a complete medical history, an extensive family pedigree, and a physical
examination. Patients undergo general laboratory, imaging, physiologic, and clinical
laboratory studies according to their disease type. Patients undergo specialized laboratory
studies including plasma and leukocyte enzyme assays, quantitative urinary
mucopolysaccharides and oligosaccharides, urine and plasma glycolipids, plasma and urine
amino acids, urine organic acids, lymphoblastoid culture, DNA isolation from peripheral
leukocytes, skin biopsy for fibroblast culture (if indicated), and medical photography.
Patients also receive consultations with various specialties including ophthalmology, ENT,
cardiology, pulmonary, gastroenterology/nutrition, hematology, neurology, orthopedics,
rehabilitation medicine/physical therapy, and dermatology.
;
Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00010361 -
Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders
|
N/A | |
| Terminated |
NCT01963650 -
Natural History Study of Children With Metachromatic Leukodystrophy
|
||
| Withdrawn |
NCT03810690 -
Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06337864 -
Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria
|
N/A | |
| Completed |
NCT00477594 -
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
|
Phase 2 | |
| Recruiting |
NCT04999566 -
Cardiac Manifestation and Inherited Metabolic Diseases
|
||
| Completed |
NCT02826694 -
North Carolina Newborn Exome Sequencing for Universal Screening
|
N/A | |
| Completed |
NCT00607373 -
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT00362180 -
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
|
Phase 2 | |
| Active, not recruiting |
NCT02635269 -
Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
|
N/A | |
| Completed |
NCT00006061 -
Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency
|
N/A | |
| Recruiting |
NCT04645498 -
COVID-19 and Hereditary Metabolic Diseases
|
||
| Completed |
NCT00099996 -
Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia
|
Phase 3 | |
| Withdrawn |
NCT02298712 -
Biomarker for Hurler Disease (BioHurler)
|
||
| Completed |
NCT00694109 -
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT05123768 -
Genetic Etiology in Patients With Cerebral Palsy
|